BIODISTRIBUTION AND PHARMACOKINETICS OF I-LABELED LEX 032, A RECOMBINANT HYBRID OF ANTICHYMOTRYPSIN
暂无分享,去创建一个
M. Thakur | H. Sands | J. Li | M. Donegan | R. Duggaraju | H. Kolan | G. A. Elove | Ramana Duggaraju | Michael Donegan | Mathew L. Thakur | LI Jirguhua | A. Gulnur | Elove
[1] A. M. Lefer,et al. Novel recombinant serpin, LEX-032, attenuates myocardial reperfusion injury in cats. , 1996, The American journal of physiology.
[2] A. M. Lefer,et al. BENEFICIAL EFFECTS OF LEX032, A NOVEL RECOMBINANT SERINE PROTEASE INHIBITOR, IN MURINE TRAUMATIC SHOCK , 1995, Shock.
[3] A. M. Lefer,et al. Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. , 1995, The Journal of pharmacology and experimental therapeutics.
[4] J. Enghild,et al. Complexes between serpins and inactive proteinases are not thermodynamically stable but are recognized by serpin receptors. , 1994, Journal of Biological Chemistry.
[5] B. Cooperman,et al. Conversion of alpha 1-antichymotrypsin into a human neutrophil elastase inhibitor: demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities. , 1994, Biochemistry.
[6] J. Enghild,et al. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. , 1991, Biochemistry.
[7] S. Pizzo,et al. Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. , 1990, Journal of Laboratory and Clinical Medicine.
[8] S. Feldman,et al. In vivo catabolism of α1-antichymotrypsin is mediated by the Serpin receptor which binds α1-proteinase inhibitor, antithrombin III and heparin cofactor II , 1988 .
[9] M. Fournel,et al. Preclinical evaluation of alpha-1-proteinase inhibitor. Pharmacokinetics and safety studies. , 1988, The American journal of medicine.
[10] R. Carrell,et al. Isolation and properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor. , 1985, The Journal of biological chemistry.
[11] J. Harlan. Leukocyte-endothelial interactions. , 1985, Blood.
[12] S. Kondo,et al. [Antithrombin III and heparin cofactor II]. , 1985, Rinsho byori. The Japanese journal of clinical pathology.
[13] M A Shifman,et al. The in vivo metabolism of antithrombin III and antithrombin III complexes. , 1982, The Journal of biological chemistry.
[14] H. Towbin,et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[15] W. Hunter,et al. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.
[16] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[17] H. Towbin,et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. , 1992, Biotechnology.
[18] S. Pizzo,et al. Hepatocyte uptake of α1‐proteinase inhibitor‐trypsin complexes in vitro: Evidence for a shared uptake mechanism for proteinase complexes of α1‐proteinase inhibitor and antithrombin III , 1984 .
[19] G. Salvesen,et al. Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.